🔗 Share this article

The first new treatments for gonorrhoea in decades are being hailed as a "significant breakthrough" in the fight against drug-resistant strains of the infection, according to health experts.

An International Public Health Issue

The sexually transmitted infection are on the rise around the world, with data suggesting over 82 million instances each year. Notably increased rates are seen in the African continent and nations within the World Health Organization's Western Pacific region, which spans from Mongolia and China to New Zealand. Within England, cases have hit a all-time high, while infection numbers across Europe in 2023 were three times higher compared to the rates from 2014.

“The clearance of novel therapies for gonorrhoea is an significant and necessary advancement in the reality of rising global incidence, the spread of superbugs and the extremely scarce treatment choices at this time.”

Medical experts are increasingly worried about the surge in treatment-resistant strains. The World Health Organization has classified it as a "priority pathogen". A tracking program showed that resistance to key first-line drugs like ceftriaxone and cefixime increased dramatically between 2022 and 2024.

A Pair of Novel Treatment Options Secure Approval

Zoliflodacin, marketed under the name Nuzolvence, was approved by the US Food and Drug Administration in mid-December for treating gonorrhoea. This infection can lead to major issues, including infertility. Experts anticipate that specific application of this new drug will help delay the spread of drug resistance.

Gepotidacin, originating from the pharmaceutical company GSK, also received approval in close succession. This drug, which is employed against UTIs, was proven in research to be successful in treating superbug versions of the gonorrhoea bacteria.

A Novel Development Model

Zoliflodacin was the result of a innovative non-profit model for medication research. The charitable organization Global Antibiotic Research & Development Partnership collaborated with the pharmaceutical company its industry partner to see it through.

“This approval represents a major breakthrough in the therapy of superbug gonorrhoea, which up to this point has been evolving faster than our drug pipeline.”

Research Study Results and Global Access

As per results detailed in a major medical journal, zoliflodacin cured more than 90% of uncomplicated infections. This places it at an similar efficacy with the typical regimen, which combines an injection and a pill. The research enrolled over 900 patients from various regions including Belgium, the Netherlands, South Africa, Thailand and the US.

As part of the agreement of its collaboration, GARDP has the authority to register and commercialise the drug in many low-income and middle-income countries.

Doctors directly involved have expressed positive views. Access to a single-dose, oral treatment such as this is hailed as a "game-changer" for public health efforts. This is considered crucial to reduce the burden of the illness for individuals and to halt the transmission of untreatable gonorrhoea around the world.